Testosterone + Hybrid Exercise for Spinal Cord Injury
Trial Summary
What is the purpose of this trial?
The proposed phase 2 trial a randomized, placebo-controlled, parallel group trial in persons with cervical or thoracic SCI, AIS grade A, B, C, or D, 6 months or later after injury. The trial will test the hypothesis that a Home-Based Multimodality Functional Recovery and Metabolic Health Enhancement Program that addresses multiple pathophysiologic factors in SCI and includes functional electrical stimulation during leg cycling (FES-LC) plus arm ergometry and an androgen will be more efficacious than functional electrical stimulation during leg cycling (FES-LC) plus arm ergometry plus placebo in improving aerobic capacity, function, metabolism, bone health, and wellbeing.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you must stop taking your current medications. However, you cannot participate if you are using testosterone or other anabolic therapies, or if you are on certain blood thinners like Coumadin, heparin, or rivaroxaban. Please consult with the trial coordinators for more details.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot participate if you have used testosterone or similar therapies in the last 6 months, or if you are on certain blood thinners like Coumadin or heparin.
What data supports the idea that Testosterone + Hybrid Exercise for Spinal Cord Injury is an effective treatment?
The available research shows that combining testosterone with hybrid exercise, which includes functional electrical stimulation (FES) and arm cycling, can improve motor function and physical fitness in individuals with spinal cord injury. Studies indicate that this treatment can increase muscle strength, endurance, and muscle size. Participants in these studies were able to perform more work during exercise, suggesting improved physical capabilities. Additionally, the treatment was shown to enhance aerobic metabolism, which is how the body uses oxygen to produce energy, indicating better overall fitness.12345
What data supports the effectiveness of the treatment Hybrid Exercise, Functional Electrical Stimulation during Leg Cycling (FES-LC) plus Arm Ergometry, and Testosterone Undecanoate for spinal cord injury?
What safety data exists for the treatment involving testosterone and hybrid exercise for spinal cord injury?
The safety data for hybrid exercise involving Functional Electrical Stimulation (FES) in spinal cord injury patients is explored in several studies. One study assessed the safety and feasibility of Hybrid High-Intensity Interval Training using FES leg cycling and arm ski ergometer, indicating it is feasible and safe. Another study examined the safety and acceptability of FES-assisted rowing, finding it safe and acceptable. However, specific safety data for the combination of testosterone treatment (Testosterone Undecanoate, Nebido, Aveed) with hybrid exercise is not directly addressed in the provided research abstracts.34678
Is the combination of testosterone and hybrid exercise safe for people with spinal cord injuries?
Is the treatment Hybrid Exercise a promising treatment for spinal cord injury?
How is the Hybrid Exercise treatment for spinal cord injury different from other treatments?
The Hybrid Exercise treatment combines functional electrical stimulation (FES) with leg cycling and arm ergometry, which is unique because it simultaneously engages both the arms and legs, potentially enhancing physical recovery and functional independence in individuals with spinal cord injury.345910
Research Team
Shalender Bhasin, MD
Principal Investigator
Brigham and Women's Hospital
Eligibility Criteria
This trial is for men and women aged 19-70 with spinal cord injury (SCI), at least 6 months post-injury, who primarily use a wheelchair. Participants must be medically stable, able to follow directions, and if female and of reproductive potential, agree to use effective contraception during the study.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Baseline Studies and Day 1
Baseline assessments and initial setup for the intervention
Treatment
Participants receive the multimodality intervention or placebo for 16 weeks
End of Study Assessments
Final assessments to evaluate the outcomes of the intervention
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Hybrid Exercise
- Testosterone Undecanoate
Find a Clinic Near You
Who Is Running the Clinical Trial?
Brigham and Women's Hospital
Lead Sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Spaulding Rehabilitation Hospital
Collaborator